ReviewJournal of the American Heart Association2025
Transcatheter Aortic Valve Durability: Focus on Structural Valve Deterioration.
Review in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07343674 (PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
Who cites it
16 citing papers in PubMed.
- Assessment of Implantation With Intra-Annular Self-Expandable Device in Transcatheter Aortic Valve Replacement.JACC. Asia · 2026Article
- Post-TAVR Neo-Sinus Geometry and Impaired Ventricular Recovery Are Associated with Early Leaflet Thrombosis: First MDCT Insights from Vietnam.Journal of clinical medicine · 2026Article
- Predicting Transcatheter Heart Valve Expansion: A New Step Toward Durable Transcatheter Aortic Valve Implantation Outcomes.Structural heart : the journal of the Heart Team · 2026Article
- Long-term valve durability and clinical outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients: a systematic review and meta-analysis of randomized trials.Journal of thrombosis and thrombolysis · 2026Review
- Sex-Specific and Time-Dependent Outcomes After TAVR Versus SAVR: A Meta-Analysis of Randomized Trials.JACC. Advances · 2026Article
- Simplifying Vascular Closure in Transfemoral TAVR: Is Less More?JACC. Asia · 2026Article
- Procedural and Device Neutrality of Post-TAVI Renal Outcomes: A Multivariable Analysis of Valve Type, Size, and Anatomy.Journal of clinical medicine · 2026Article
- Impact of Anticoagulant Class on Long-Term Bioprosthesis Durability Following Transcatheter Aortic Valve Replacement.Structural heart : the journal of the Heart Team · 2026Article
- A looming wave of bioprosthetic transcatheter valve failure?-rethinking lifetime management and reintervention in aortic stenosis.Journal of visualized surgery · 2026Article
- Bioprosthetic heart valve degeneration: new insights into structural remodeling and calcification.Frontiers in cardiovascular medicine · 2026Review
- Association of SGLT2 Inhibitors with Mortality and Bioprosthesis Valve Failure After TAVR: A Propensity-Matched Cohort Study.Journal of clinical medicine · 2025Article
- Article
- Subclinical Leaflet Thrombosis and Subclinical Aortic Valve Complex Thrombosis in TAVR.JACC. Advances · 2025Review
- A "Watchful Surgery" Approach: Timing and Valve Choice for Mildly Symptomatic Mitral and Aortic Valve Disease.Journal of surgery and research · 2025Article
- Mechanotransduction of autotransplants: remodeling potential of heart valves from autologous pericardial tissue.Frontiers in bioengineering and biotechnology · 2025Review
- Cost Implications and Perspectives of TAVI versus SAVR in the Hospital Setting.Arquivos brasileiros de cardiologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement has emerged as a valuable alternative to surgical aortic valve replacement in patients with severe aortic stenosis. Given the expansion of transcatheter aortic valve replacement to lower-risk and younger populations with longer life expectancy, the durability of transcatheter heart valves (THVs) has become an important issue that may impact cardiovascular outcomes. THVs share similarities with surgical valves but have unique features, including a trend to larger effective orifice area and less prosthesis-patient mismatch, interactions with the native valve, and crimping process, that may all potentially influence a THV's life span. Multiple mechanisms may lead to bioprosthetic valve dysfunction, including structural valve deterioration, thrombosis, endocarditis, and nonstructural valve deterioration. With an incidence of up to 12.3% 5 years after transcatheter aortic valve replacement, structural valve deterioration represents the ultimate consequence of fibrotic remodeling and calcification within the bioprosthesis, driven by thrombotic and inflammatory processes involving the native aortic valve and influenced by patient and procedural factors. Understanding these mechanisms is crucial for improving THV durability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.